Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus FLORONE E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus FLORONE E.
CORTONE vs FLORONE E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
FLORONE E contains diflorasone diacetate, a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and reducing prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
Apply a thin film to affected skin area twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Approximately 2-4 hours (terminal) for the active moiety diflorasone; clinically, this supports twice-daily dosing for chronic skin conditions.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Primarily renal (<1% unchanged as metabolite) and biliary, with <1% excreted unchanged in urine. The remainder is metabolized and excreted in feces via bile.
Category C
Category C
Corticosteroid
Corticosteroid